Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in June 2023
Insights+: EMA Marketing Authorization of New Drugs in June 2023
Shots: The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in June 2023, leading to treatments for patients and advances in the healthcare industry In June 2023, the major highlights drugs were Jardiance approval for CKD patients, Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis PharmaShots has compiled a list of a…
July 28, 2023
Know Your Investor: Qiming Venture Partners
Know Your Investor: Qiming Venture Partners
Shots: Our brand-new report, Know Your Investor, is an earnest effort to acquaint our readers with the major investors in the market. Every month PharmaShots aims to bring an informative report on investors and venture capital firms  Our pilot report focuses on Qiming Venture Partners, which is based out of China and has headquarters in…
July 27, 2023
Top Performing Drug – Ocrevus (July Edition)
Top Performing Drug – Ocrevus (July Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus  Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS PharmaShots presents…
July 26, 2023
Insights+: The US FDA New Drug Approvals in June 2023
Insights+: The US FDA New Drug Approvals in June 2023
Shots: The US FDA approved 12 NDAs and 3 BLA in June 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 69 novel products in 2023 In June 2023, the major highlights drugs were Talzenna + Xtandi approval for prostate cancer, Rystiggo for generalized myasthenia gravis PharmaShots…
July 19, 2023
New Drug Designations - June 2023
New Drug Designations – June 2023
Shots:  PharmaShots' designation report provides a condensed overview of several drugs and their designations by the US FDA, the EU, China, and the UK. This month’s report includes 7 biological drugs, 13 small molecules and 9 cell and gene therapies  CellCentric’s Inobrodib, for multiple myeloma and Rocket Pharmaceuticals’ RP-A601, for PKP2-arrhythmogenic cardiomyopathy were the two…
July 17, 2023
Disease of the Month- Juvenile Arthritis
Disease of the Month- Juvenile Arthritis
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings this month a summary of Juvenile arthritis, an autoimmune inflammatory disease   July is observed…
July 13, 2023
Insights+ Key Biosimilars Events of June 2023
Insights+ Key Biosimilars Events of June 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of June, Samsung Bioepis presented results of SB12…
July 5, 2023
PharmaShots' Key Highlights of Second Quarter 2023
PharmaShots’ Key Highlights of Second Quarter 2023
Shots: The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9B The second quarter of the year also showcases multiple approvals of the therapies…
July 3, 2023
Top Performing Drug – Enbrel (June Edition)
Top Performing Drug – Enbrel (June Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023
Insights+: EMA Marketing Authorization of New Drugs in May 2023
Insights+: EMA Marketing Authorization of New Drugs in May 2023
Shots: The EMA approved 3 New Chemical Entity (NCE) and 7 Biologic Drugs in May 2023, leading to treatments for patients and advances in the healthcare industry In May 2023, the major highlights drugs were Breyanzi’s Approval for relapsed or refractory large B-cell lymphoma, Ultomiris (ravulizumab) for neuromyelitis optica spectrum disorder PharmaShots has compiled a…
June 26, 2023
Load more